Navigation Links
Alfacell Provides ONCONASE(R) NDA Submission Update
Date:12/5/2008

SOMERSET, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported that the U.S. Food and Drug Administration (FDA) has scheduled a pre-NDA meeting date at the end of January 2009 for discussion of the company's planned submission of the final components of the ONCONASE rolling New Drug Application (NDA) for the treatment of unresectable malignant mesothelioma (UMM) patients. The pre-NDA meeting is an important step to complete prior to the planned submission of the final components of the ONCONASE rolling NDA for patients that have failed prior chemotherapy. Therefore, the final components of the rolling ONCONASE NDA will not be finalized until Alfacell receives guidance from the FDA at the pre-NDA meeting. Alfacell expects to provide an update on the planned completion of the rolling NDA within 48 hours of the conclusion of the pre-NDA meeting.

As the company has previously reported, the results of the preliminary statistical analysis of the data from the confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from UMM did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need.

Since receiving the results of this preliminary statistical analysis in late May 2008, the company engaged in an extensive and careful review of the data to submit to the FDA prior to the pre-NDA meeting. While preparations of materials for the pre-NDA meeting have taken more time than expected, by submitting the pre-NDA meeting request on October 3, 2008, Alfacell had anticipated that the pre-NDA meeting wo
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
2. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
3. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
4. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... The Netherlands , February 9 ... as CEO of Hoya Vision Care,Europe starting the 1st of ... Gerald W.,Bottero , who has been leading the European branch ... Hoya Vision Care globally. ,, Mr. ... is,currently President of Hoya Lens Belgium and Hoya Lens France. ...
(Date:2/9/2010)... Feb. 9 Sanofi-aventis (EURONEXT: SAN ... it has successfully completed its tender offer for all ... CHTT).   ,, The tender offer and withdrawal rights ... time, on February 8, 2010 .  The depositary ... of the expiration time, approximately 18,611,072 shares of Chattem ...
(Date:2/8/2010)... , Feb. 8 Cost reductions ... Products (Nasdaq: AHPI ) narrowly back into profitability ... Sales for the quarter ended December 31, 2009 ... million during the same quarter last year to ... Allied,s costs of sales were reduced even more sharply, ...
Breaking Medicine Technology:New CEO for Hoya Vision Care Europe 2Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 2Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 3Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 4Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc. 5Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 2Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 3Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 4Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 5Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions 6St Elizabeth Healthcare Drives Kentuckys Largest Electronic Medical Records Initiative With IBM 53145 1St Elizabeth Healthcare Drives Kentuckys Largest Electronic Medical Records Initiative With IBM 53145 2St Elizabeth Healthcare Drives Kentuckys Largest Electronic Medical Records Initiative With IBM 53145 3Roxane Laboratories Inc Announces the Launch of Risperidone Oral Solution 1mg mL 53140 1Roxane Laboratories Inc Announces the Launch of Risperidone Oral Solution 1mg mL 53140 2Neurocrine Biosciences Reports Second Quarter 2009 Results 13258 1Neurocrine Biosciences Reports Second Quarter 2009 Results 13258 2Neurocrine Biosciences Reports Second Quarter 2009 Results 13258 3Neurocrine Biosciences Reports Second Quarter 2009 Results 13258 4Neurocrine Biosciences Reports Second Quarter 2009 Results 13258 5Neurocrine Biosciences Reports Second Quarter 2009 Results 13258 6Neurocrine Biosciences Reports Second Quarter 2009 Results 13258 7
... UCB offers Cimzia(R) (certolizumab pegol), a treatment option ... arthritis and moderate to severe Crohn,s disease, to ... resulting from the UCB partnership with OXO(R) ... and OXO(R) in the development of the new ...
... U.S.D.A. Animal Studies: Chromium Picolinate and Chromium Histidinate ... Studies Continue to Demonstrate Safety and Efficacy of ... Nutrition 21, Inc. (Nasdaq: NXXI ... under the Iceland Health(R) and Diabetes Essentials brands, ...
Other Medicine Technology:Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 2Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 3Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 4Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 5Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 6Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 7Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 8Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 9Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 10Video: Partnership Unites UCB with Consumer Product Innovator OXO(R) 11New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 2New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 3New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 4
(Date:2/9/2010)... Excellence in Reporting, Portrayals of Mental Health Issues; ... ,, ALEXANDRIA, Va. , Feb. ... journalists and media professionals to submit national, state, ... print, online radio, television and film for the ... a downloadable entry form, are available at ...
(Date:2/9/2010)... Sheila Doss , BSN, RN, CNN, ... re-elected Western Chapters Coordinator-Elect (CCE) of the American ... Doss, Nursing Director of Research of Satellite Healthcare will ... in San Antonio, TX , May ... coordinate and supervise regional chapter activities, report to the ...
(Date:2/9/2010)... and Stimulus Resource Library featured on redesigned MxSecure, Inc. site: ... ... AZ (PR WEB) February 9, 2010 -- Medical transcription ... the launch of their new website., , , , ,Improving ... MxSecure,s revamped website, and it captures the focus of all ...
(Date:2/9/2010)... Benefits American Heart Association’s Go Red For Women® Movement to ... Counties. , ... Central Coast, CA ... San Luis Obispo and Santa Barbara Counties announce their participation ... Life campaign that launched on February 1, 2010. Benefiting ...
(Date:2/9/2010)... Manhattan Research’s Health Influence Mapping Research Module Helps Marketers ... Consumer Health Behavior , ... ... February 9, 2010 -- The Internet has considerably more ... channels like print, TV and radio, according to pharmaceutical ...
Breaking Medicine News(10 mins):Health News:Mental Health America Encourages Journalists, Media Professionals to Submit Entries for 2010 Media Awards 2Health News:Mental Health America Encourages Journalists, Media Professionals to Submit Entries for 2010 Media Awards 3Health News:Satellite Healthcare's Sheila Doss Elected Western Chapters Coordinator-Elect of the American Nephrology Nurses' Association 2Health News:Satellite Healthcare's Sheila Doss Elected Western Chapters Coordinator-Elect of the American Nephrology Nurses' Association 3Health News:Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity 2Health News:Central Coast Jiffy Lube Service Centers Embark on Year Three of Successful Maintenance Partners For Life Campaign 2Health News:Central Coast Jiffy Lube Service Centers Embark on Year Three of Successful Maintenance Partners For Life Campaign 3Health News:Central Coast Jiffy Lube Service Centers Embark on Year Three of Successful Maintenance Partners For Life Campaign 4Health News:New Report: The Internet Has More Influence Over Consumer Health Actions than Traditional DTC Channels 2Health News:New Report: The Internet Has More Influence Over Consumer Health Actions than Traditional DTC Channels 3Health News:New Report: The Internet Has More Influence Over Consumer Health Actions than Traditional DTC Channels 4Health News:New Report: The Internet Has More Influence Over Consumer Health Actions than Traditional DTC Channels 5
... doctors in St Helens Hospital, Tasmania have been blamed on ... Excessive workload was the reason given by most doctors for ... Cerchez there have been more doctors recruited to St Helens ... high turnover is to internal issues. , He ...
... dishes in the menu of the Aiwan-e-Sadar, President's House, ... told the National Assembly that chicken dishes have been ... where foreigners and diplomats are invited. This is part ... he said in a reply to a question. ...
... of vitamin C and E supplements during pregnancy in no ... in healthy women//. ,Preeclampsia is a condition in ... pregnancy elevated blood pressure at a level that could potentially ... ,According to foodconsumer.org, the study of nearly 2000 women in ...
... water filtration system, powered by bicycle that can be ... (NTU) institute of environmental science and engineering unveiled the ... pump and a membrane module to filter the water. ... experts said it is an improvement on the hand-cranked ...
... to for help with their weight problems. According to a ... the obese in getting back to shape. Incidentally, Oxyntomodulin is ... feelings of satiation, or Feeling Full. , ,Steve Bloom ... men and women. The study participants belonged to the age ...
... in ducks on Indonesia's resort island of Bali, health ... had been smuggled to Bali from the adjacent Java ... ,More than 24 bird flu related deaths ... nation. In response to the above situation, import of ...
Other Medicine News:Health News:Preeclampsia Risk Can't Be Overcome By Taking Antioxidants 2Health News:Hormone - A Shot in the Arm for Weight Loss 2
This Wright-Giemsa is a dual-use stain for peripheral blood and bone marrow smears. It produces somewhat darker results when compared with Giemsa, particularly in the blue to magenta shades....
RABIT (Rapid Automated Bacterial Impedance Technique) has been developed by Don Whitley Scientific over several years with the aid of leading product and computer design consultants....
Albumin FS for determination of albumin in serum or plasma. For Hitachi 704 / 911. Available with Calibrator: Trucal U and Controls: Trulab N and Trulab P....
Intended for the quantitative determination of albumin in serum or plasma. Reaction: Endpoint. Wavelength: 628 nm. Linearity: 8 g/dl (80 g/l). Ready to use liquid reagent....
Medicine Products: